( *| 33* | |--------+---...)Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis,Health

* p<0.001

011 Trial
In the 24-week 011 phase III study, 220 adult patients with active RA who had previously failed at least one DMARD were randomized to
receive either CIMZIA(TM) 400 mg given subcutaneously every four weeks (n=111) or placebo (n=109). Patients were assessed for
improvement in signs and symptoms of RA. The primary endpoint of the 011 study was ACR20 responder rate, with secondary measures including ACR50 and ACR70 responder rates.

About Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a progressive autoimmune disease which causes chronic inflammation of the joints. It is estimated that 5
million people suffer from RA globally,[2] with 0.3% to 1% of the population in industrialized countries suffering from RA.[3]

Prevalence is not split evenly between genders, since women are three times more likely to be affected than men.[4] Although it can affect
people of all ages, the onset of RA usually occurs between the ages of 35-55 years.[5]

Symptoms of RA include joint stiffness, joint pain, inflammation of the affected areas and an associated reduction in mobility. These
symptoms can be intermittent and vary in severity from patient to patient. In more severe cases RA can eventually lead to disability.
RA patients are also at a higher risk of developing other conditions, in particular heart disease, stroke, infections, lung problems and
osteoporosis.[6]

As there is currently no cure for RA, treatment goals centre on disease management. Treatment is aimed at controlling disease
progression, providing pain relief and reducing swelling, preventing joint damage and deformity and maintaining function of the a
'"/>